Details for Patent: 5,138,069

Scope, Claims, and US Patent Landscape for US Drug Patent 5,138,069

What does US 5,138,069 claim, at the highest level?

US Patent 5,138,069 claims a class of antihypertensive small-molecule compounds defined by a shared core scaffold and extensive variable substituent definitions across multiple ring positions and linker atoms (claims 1–39). It is a genus patent: Claim 1 sets broad structural rules for an “antihypertensive compound of the formula” with a large combinatorial space of substituents and then narrows via (i) claim dependencies and (ii) dozens of explicit provisos that exclude specific embodiments.

The patent also includes a set of specific exemplified species by dependency chain (claims 5–27 and later claims 38–39). Those species anchor infringement risk because many likely commercial candidates map into that defined exemplified region.

How broad is Claim 1 in structural coverage?

Claim 1 is drafted as a formula with variables R1–R8, additional substitution layers R9–R16, conditional linker choices (X, Y, Z), and range constraints for linkage atom counts (m, n, p, q, r, s, t). It further adds multi-part provisos that remove subsets of the theoretical genus.

Claim 1 core substituent variables (high-level)

• R1: defined as a large substituent family (includes aryl-like fragments and ring-bearing groups via multiple “##STR####” definitions), with explicit positional restrictions (proviso (1), and additional provisos tied to R1 subclasses).
• R2: enumerates H and multiple halogens (Cl, Br, I, F), plus NO2, CN, and aliphatic/functional groups including 1–4C alkyl, 1–4C acyloxy, 1–4C alkoxy, CO2H / CO2R9, and sulfonamide motifs (NHSO2CH3, NHSO2CF3), plus an additional variable group family tied to “##STR489”.
• R3: defined to H, Cl/Br/I/F, 1–4C alkyl/alkoxy, and a “R4-like” position (with R4 defined below).
• R4: limited to CN, NO2, or CO2R11.
• R5: broad functional latitude: H, alkyl 1–6C, cycloalkyl 3–6C, alkenyl/alkynyl 2–4C.
• R6: broad hydrophobic/lipophilic space: large alkyl 2–10C, alkenyl/alkynyl 3–10C with allowed F or CO2R14 substitution, plus multiple cycloalkyl and cycloalkylalkyl/cycloalkylalkenyl/cycloalkylalkynyl families.
• R7 and R8: each includes halogens, CN and multi-carbon alkyl/aryl-like substituents, plus specific heteroaryl-like fragments for R8 such as imidazol-1-yl, 1,2,3-triazolyl, and tetrasolyl variants, plus optional alkyl/CO2CH3 substitution on the heteroaryl.
• R9–R13: additional expansion of terminal groups and acidic/ester functionalities (e.g., CO2H / CO2R9 / NHSO2CF3 / sulfonated or acyl-like options).
• R14–R16, R17–R19, R20–R31, X/Y/Z: define secondary substituent families, choice of linker atoms/bonds, and ring-closure contexts.

Claim 1 linker and ring-closure scope

• X: may be a C-C single bond or multiple heteroatom-containing linkers including CO, CH2, O, S, plus numerous other defined structural bridges (e.g., sulfonamide/urea-like and unsaturated motifs such as CH═CH, CF═CF, CH═CF, CF═CH variants).
• Y: O or S
• Z: O, NR11, or S
• Count variables: m = 1–5, n = 1–10, p = 0–3, q = 2–3, r = 0–2, s = 0–5, t = 0–1

Claim 1 explicit exclusion list (proviso set)

Claim 1 then narrows by 15+ explicit constraints that carve out subsets, including:

1. R1 not in the ortho position.
2. When R1 = ##STR498##, with conditions on X being single bond and R13 being CO2H (positional rules) or NHSO2CF3 / NHSO2CH3 (ortho restriction).
3. When R1 = ##STR500## and X other than a single bond, then R13 must be ortho, with an exception when X = NR23CO and R13 is sulfonamide CF3/CH3 requiring ortho or meta.
4. When R1 is 4-CO2H (or salt), R6 cannot be S-alkyl.
5. When R1 is 4-CO2H (or salt), the substituent at imidazole 4-position cannot be CH2OH, CH2OCOCH3, or CH2CO2H.
6. When R1 = ##STR501##, X = OCH2 and R13 = 2-CO2H, and R7 = H, then R6 is not C2H5S.
7. When R1 = ##STR502## and R6 = n-hexyl, then R7 and R8 cannot both be hydrogen.
8. When R1 = ##STR503##, then R6 is not methoxybenzyl.
9. R6 is not ##STR504##. 10–11. When r = 0, with specific R1/X/R13/R6 combinations, then R7 and R8 are not CO2CH3 (two separate variants for R1 variants). 12–13. When r = 1, with specific R1/X/R7/R8 combos, then R13 is not tetrasol-5-yl (and positional variant 4 vs 3).
10. When r = 0, then R1 is not 4-NHSO2CH3 or 4-NHSO2CF3.

These provisos create a structured “negative space”: the infringement-relevant question becomes whether an accused compound lands inside the genus without violating any enumerated exclusion.

How does Claim 2–4 narrow to a “workable” sub-genus?

• Claim 2: narrows to a subset where:
  • R1 is limited to CO2H or NHSO2CF3.
  • R6 and R8 are further constrained to defined ranges and specific options.
  • R13 is constrained to: CO2H, CO2R9, NHSO2CF3, SO3H, or ##STR514.
  • X limited to C-C single bond, CO, or other specific bridges.
• Claim 3: narrows further:
  • R2 restricted to H/1–4C alkyl/halo/1–4C alkoxy.
  • R6 limited to 3–7C alkyl/alkenyl/alkynyl.
  • R7 restricted to H, halogens, CvF2v+1 with v=1–3, or ##STR516.
  • R10, R11, R13, R14, R15, R16 each restricted to specific sub-families.
  • X narrowed to a fixed list including: single bond, O-, CO-, NHCO-, OCH2-.
• Claim 4: pins to the “center” species family:
  • R1 = ##STR520##
  • X = single bond

In practice, the claim chain suggests the patent is built around a limited “core pharmacophore” region, while the earlier Claim 1 provides broad formula language and the later claims supply the dominant commercially relevant embodiments.

What specific compounds are claimed as dependent species?

The dependent claims (5–27) list numerous explicit structures by chemical name. These likely correspond to exemplified entries in the specification. The list includes:

• Claim 5: 2-Butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole (or salt)
• Claim 6: 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-(hydroxymethyl)-imidazole (or salt)
• Claim 7: 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-[(methoxycarbonyl)-aminomethyl]imidazole (or salt)
• Claim 8: 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-[(propoxycarbonyl)-aminomethyl]imidazole (or salt)
• Claim 9: 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]imidazole-5-carboxaldehyde (or salt)
• Claim 10: 2-Butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]imidazole-5-carboxaldehyde (or salt)
• Claim 11: 2-(1E-Butenyl)-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole (or salt)
• Claim 12: 2-(1E-Butenyl)-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]imidazole-5-carboxaldehyde (or salt)
• Claim 13: 2-propyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-(hydroxymethyl)imidazole (or salt)
• Claim 14: 2-propyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde (or salt)
• Claim 15: 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde (or salt)
• Claim 16: 2-(1E-butenyl)-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-(hydroxymethyl)imidazole (or salt)
• Claim 17: 2-(1E-butenyl)-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxaldehyde (or salt)
• Claim 18: 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid (or salt)
• Claim 19: 2-propyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid (or salt)
• Claim 20: 2-propyl-4-trifluoromethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-methyl]imidazole-5-carboxylic acid (or salt)
• Claim 21: 2-propyl-4-trifluoromethyl-1-[(2'-1H-tetrazol-5-yl)biphenyl-4-yl)-methyl]imidazole-5-(hydroxymethyl)imidazole (or salt)
• Claim 22: 2-butyl-4-trifluoromethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-methyl]imidazole-5-carboxylic acid (or salt)
• Claim 23: 2-propyl-4-trifluoromethyl-1-[(2'-(carboxybiphenyl-4-yl)methyl]-imidazole-5-carboxaldehyde (or salt)
• Claim 24: 2-propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole (or salt)
• Claim 25: 2-propyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-4,5-dicarboxylic acid (or salt)
• Claim 26: 2-propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid (or salt)
• Claim 27: 2-propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde (or salt)

Later independent/species claims:

• Claim 38: 1-[(2'-carboxybiphenyl-4-yl)methyl]-4-phenyl-2-propylimidazole-5-carboxaldehyde
• Claim 39: 2-propyl-4-phenyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde

Where is the patent “thick” for enforceability? (claim architecture)

The likely enforceability stack is:

1. Broadest Claim 1 (genus) establishes a wide infringement net and supports doctrine-of-equivalents-style arguments for close variants, subject to the explicit provisos.
2. Claim 2–4 define a narrower subset with more fixed pharmacophoric features.
3. Dependent species claims identify particular substitution patterns, supporting both literal infringement and validity-defense triangulation.

For a competitor, the key design-around failure mode is to modify substituents while leaving the core scaffold and “positional constraints” intact.

What is the patent landscape around US 5,138,069?

What can be concluded from the claim text provided

The text you provided contains only the claims and the constraint language inside US 5,138,069. It does not include:

• publication number(s) and priority data,
• prosecution history,
• cited prior art,
• family members (continuations/divisionals),
• other US patents or PCT publications covering the same chemistry,
• prosecution outcomes or terminal disclaimers,
• maintenance status, expiration, or settlement outcomes.

Because those items are required to map a credible “landscape” (not just a descriptive genus), no defensible cross-patent comparison can be produced from the claim text alone.

Landscape implications that do follow directly from the claims themselves

Even without external patent citations, the claim design indicates the following competitive zones:

• Tetrazole vs carboxyl “terminal” options: Claim 1 and the dependent species alternate between (1H-tetrazol-5-yl)-substituted biphenyl and carboxy-substituted biphenyl (claims 5 vs 6; claims 18 vs 6/9 patterns). That suggests prior art chemistry treated these as interchangeable or closely related pharmacophores.
• Imidazole 5-position oxidation state space: species include hydroxymethyl, carboxaldehyde, carboxylic acid, and protected carboxylate/aminomethyl derivatives (claims 5, 9, 18, 7, 8). That implies competitors that target different metabolism/PK forms still risk claim coverage if within the R6/R7/R8/R13/R14 constraints.
• Halogen and perfluoroalkyl substitution: species include trifluoromethyl and pentafluoroethyl at a defined ring position (claims 20, 22, 24–27). This points to a latitude for potency optimization that remains inside the same claim family.

Risk map: which claim variables are the highest leverage for design-around?

A practical risk triage based only on the claim provisos and dependency constraints:

1. R1 positional restriction: “R1 group is not in the ortho position” (proviso (1)). This is a hard exclusion.
2. R13 positional rules tied to R1 and X: multiple provisos require ortho or meta placement when R1 takes specific defined forms and when X is a single bond or not. This is likely where many near-misses fail.
3. R6 exclusions:
   • “R6 cannot be S-alkyl” when R1 is 4-CO2H (proviso (4)).
   • “R6 is not methoxybenzyl” under a defined R1 case (proviso (8)).
   • “R6 is not ##STR504##” (proviso (9)).
   • additional conditional restrictions for particular r=0 cases tied to R7/R8 not both hydrogen or not both CO2CH3.
4. Imidazole substituent restrictions under carboxy-bearing R1:
   • the 4-position imidazole substituent cannot be CH2OH, CH2OCOCH3, CH2CO2H when R1 is 4-CO2H.
5. R13 forbidden tetrasol-5-yl embodiments under r=1 and defined R1/X/R7/R8 situations (provisos (12) and (13)).

These are the “hard walls” because they directly state what is not allowed inside the claim boundaries.

What’s the “most litigable” claim set?

Given the claim text, the most litigable combination is:

• Claim 4 (fixing R1 = ##STR520## and X = single bond) as the gateway, because it collapses the linker ambiguity.
• Then dependent species (claims 5–27), because they list concrete chemical identities rather than broad genus variations.
• Claim 38–39 add two further named aldehyde species with 4-phenyl at a defined imidazole position, expanding the specific-species zone beyond the earlier tetrazole/carboxyl patterns.

Key Takeaways

• US 5,138,069 is a genus-plus-species antihypertensive patent: Claim 1 defines a very large combinatorial chemical space, while Claims 2–4 and dependent claims substantially narrow it to the most specific pharmacophore variations.
• The claim set has hard exclusions (multiple provisos) that restrict ortho/meta positioning (R1 and R13) and forbid specific R6 and imidazole 4-position/5-position substitution patterns under defined conditions.
• Enforcement risk concentrates in the dependent species claims, because they identify named embodiments (including tetrazole- and carboxy-biphenyl variants; hydroxymethyl, carboxaldehyde, carboxylic acid, and protected aminomethyl derivatives; and CF3/pentafluoroethyl substitutions).
• A credible multi-patent “landscape” cannot be constructed from the claim text alone; the claims provided do not include citation lists, family members, priority/publication metadata, or prosecution details needed to map related US/IP assets.

FAQs

1. Is US 5,138,069 primarily a composition-of-matter patent or a method-of-treatment patent?
   The claims are for antihypertensive compounds defined by chemical formula variables and salts, i.e., a composition-of-matter claim structure.

2. Does Claim 1 cover both tetrazole and carboxyl terminal substituents?
   Yes. The claim set includes R8-linked heteroaryl options (e.g., imidazolyl/triazolyl/tetrazolyl) and species explicitly include tetrazol-5-yl biphenyl and carboxy-biphenyl variants.

3. Which parts of Claim 1 most directly support a design-around?
   The explicit provisos. The strongest levers are the positional restrictions (R1 not ortho; R13 ortho/meta requirements tied to R1 and X) and the R6 exclusion conditions.

4. Are specific commercial-looking candidates likely to fall under the dependent claims?
   The patent includes many named species (claims 5–27, 38–39) across aldehyde, acid, hydroxymethyl, and protected derivatives with halogen and perfluoroalkyl substitutions, so literal matches are plausible for close analogs.

5. Can a full US patent landscape be determined from the provided claim text?
   Not in a defensible way. A landscape requires patent family data, citations, and external documents, none of which appear in the claim excerpt.

References

[1] United States Patent 5,138,069, “Antihypertensive compounds,” claims 1–39 (claim text provided).